Royalty Pharma Sub-Manager, LLC

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed August 21, 2026), Royalty Pharma Sub-Manager, LLC reported 4 stock positions worth $171.3 million. Its top holding was Cytokinetics (CYTK) at 36.4% of the portfolio, followed by Zenas Biopharma (ZBIO, 26.8%) and Biohaven (BHVN, 19.4%).

Most Recent 13F
Q2 2026
Location
New York, NY
CIK
0002081668
Portfolio Value
$171.3M (Q4 2025)
SEC Filing
0002081668-26-000015 ↗ filed Aug 21, 2026

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q4 2025: $171.3M $171.3M Q4 2025 Q1 2026: $172.8M Q1 2026 Q2 2026: $241.9M Q2 2026

Holdings 4 stocks · $171.3M
CYTK Cytokinetics Inc. 36.36% 980,392 $62.3M —
ZBIO Zenas Biopharma Inc. 26.77% 1,263,150 $45.9M —
BHVN Biohaven Ltd. 19.35% 2,936,507 $33.2M —
BCRX Biocryst Pharmaceuticals Inc. 17.51% 3,846,154 $30.0M —

Portfolio Sells Q4 2025

No earlier filing to compare with.

Portfolio Buys Q4 2025

No earlier filing to compare with.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026Amended 4$241.9MCYTK, ZBIO, KLRA, BHVN
Q1 2026Amended 4$172.8MCYTK, ZBIO, BCRX, BHVN
Q4 2025Amended 4$171.3MCYTK, ZBIO, BHVN, BCRX